HCV Policy & Advocacy
EASL 2016: Cost of Eliminating Viral Hepatitis Must Consider Social as Well as Medical Factors
- Details
- Category: HCV Policy & Advocacy
- Published on Thursday, 05 May 2016 00:00
- Written by Keith Alcorn
Securing commitments from national governments to treat viral hepatitis, scale up prevention activities, and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces -- and a sophisticated approach to proving the value of investing in elimination of viral hepatitis -- delegates heard at last month’s EASL International Liver Congress.
EASL 2016: How Generic Direct-Acting Antivirals Are Changing the Hepatitis C Treatment Landscape
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 22 April 2016 00:00
- Written by Keith Alcorn
The arrival of generic versions of direct-acting antivirals (DAAs) is transforming the global hepatitis C treatment landscape and highlighting the overlooked importance of the cost of monitoring technologies, presenters said at the EASL International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 15 April 2016 00:00
- Written by Liz Highleyman
Leaders of liver disease associations from Europe, the U.S., Latin America, and Asia released a Joint Society Statement on Elimination of Viral Hepatitis at the opening session of the International Liver Congress (EASL 2016) this week in Barcelona, calling for enhanced efforts to diagnose and treat hepatitis B and C, with the goal of eliminating viral hepatitis as a public health threat.
EASL 2016: Low-Cost Generic Hepatitis C Drugs Match Branded Products in Viral Response
- Details
- Category: HCV Policy & Advocacy
- Published on Saturday, 16 April 2016 00:00
- Written by Keith Alcorn
Generic versions of direct-acting antivirals for hepatitis C purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as the branded products, a study of 139 patients monitored by Australian doctor James Freeman has shown. The findings were presented in a late-breaking research session at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona on Saturday.
FY 2017 Budget Sustains HIV Funding, Requests More for PrEP, Opioid Epidemic
- Details
- Category: HIV Policy & Advocacy
- Published on Wednesday, 17 February 2016 00:00
- Written by Liz Highleyman
President Barack Obama's proposed budget for fiscal year 2017 modestly increases funding for domestic HIV services -- with $20 million allocated for a pre-exposure prophylaxis (PrEP) pilot programand $9 million for HIV/HCV coinfection -- but flat funds HIV research and global AIDS assistance. The budget also address the growing opioid epidemic and includes efforts to expand Medicaid and reduce prescription drug costs.
More Articles...
- 9. HIV and Hepatitis C Treatment Cost and Barriers to Access
- Sofosbuvir/Daclatasvir Combination Could Be Produced for $200 per Hepatitis C Cure
- AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
- AASLD 2015: Liver Doctors and Advocates Call for Wider Treatment of People with Hepatitis C
Web Design and Development by